CoChat
Sign Up
Cited by 8Attention Deficit Hyperactivity DisorderPharmaceutical studies and practicesPharmacology and Obesity Treatment

Lisdexamfetamine in the treatment of adolescents and children with attention-deficit/hyperactivity disorder

Open access
Najib, Jadwiga·2012·Adolescent Health, Medicine and Therapeutics
DOI 10.2147/ahmt.s19815PMC PMC3915893
Open this paper in CoChat — free accountOpen PDF

Abstract

Attention-deficit/hyperactivity disorder is one of the most common neurobehavioral disorders defined by developmentally inappropriate levels of inattention, hyperactivity, and impulsivity. Symptoms begin in childhood and may persist into adolescence and adulthood. Currently available pharmacological treatment options for attention-deficit/hyperactivity disorder in children and adolescents include stimulants that are efficacious and well tolerated; however, many of these preparations require multiple daily dosing and have the potential for abuse. Lisdexamfetamine dimesylate, the first prodrug stimulant, was developed to provide a longer duration of effect. It demonstrates a predictable delivery of the active drug, d-amphetamine, with low interpatient variability, and has a reduced potential for abuse. A literature search of the MEDLINE database and clinical trials register from 1995-2011, as well as relevant abstracts presented at annual professional meetings, on lisdexamfetamine dimesylate in children and adolescents were included for review. This article presents the pharmacokinetic profile, efficacy, and safety of lisdexamfetamine dimesylate for the treatment of attention-deficit/hyperactivity disorder in children and, more recently, in adolescents.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2147/ahmt.s19815

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • LDX is approved for ADHD use in children, adolescents, and adults in the United States, Canada, Denmark, Finland, Germany, Ireland, Norway, Spain, Sweden, and the United Kingdom, and in children in Brazil.

    “Lisdexamfetamine dimesylate is approved for ADHD use in children, adolescents, and adults in the United States (Vyvanse), Canada (Vyvanse), Denmark (Elvanse), Finland (Elvanse) Germany (Elvanse), Ireland (Tyvense), Norway (Elvanse), Spain (Elvanse), Sweden (Elvanse), and United Kingdom (Elvanse) and in children in Brazil (Venvanse).”

    From Review of Lisdexamfetamine Dimesylate in Adults With Attention-Deficit/Hyperactivity Disorder (2017) · cites this paper as [11]

    The ADHD management section says LDX was approved for children in 2007 and adolescents in 2010; the Adolescents section specifies FDA approval for adolescents in the United States. The paper does not establish approval for adults or the claimed approvals in Canada, the listed European countries, or Brazil, nor does it provide the brand names. (LLM, conf=0.90)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 45

  1. [1]Wolraich ML Wibbelsman CJ Brown TE Attention-deficit/hyperactivity disorder among adolescents: a review of the diagnosis, treatment, and clinical implications Pediatrics 2005 115 6 1734 1746 15930238
  2. [2]Subcommittee on Attention-Deficit/Hyperactivity Disorder, Steering Committee on Quality Improvement and Management ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents Pediatrics 2011 128 5 1007 1022 22003063 PMC4500647
  3. [3]Froehlich TE Lanphear BP Epstein JN Barbaresi WJ Katusic SK Kahn RS Prevalence, recognition, and treatment of attention-deficit/hyperactivity disorder in a national sample of US children Arch Pediatr Adolesc Med 2007 161 9 857 864 17768285
  4. [4]Green JG Avenevoli S Finkelman M Attention deficit hyperactivity disorder: concordance of the adolescent version of the Composite International Diagnostic Interview Version 3.0 (CIDI) with the K-SADS in the US National Comorbidity Survey Replication Adolescent (NCS-A) supplement Int J Methods Psychiatr Res 2010 19 1 34 49 20191660 PMC2938790
  5. [5]Doyle AE Executive functions in attention-deficit/hyperactivity disorder J Clin Psychiatry 2006 67 Suppl 8 21 26 16961426
  6. [7]Pliszka S AACAP Work Group on Quality Issues Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder J Am Acad Child Adolesc Psychiatry 2007 46 7 894 921 17581453
  7. [8]Kutcher S Aman M Brooks SJ International consensus statement on attention-deficit/hyperactivity disorder (ADHD) and disruptive behavior disorders (DBDs): clinical implications and treatment practice suggestions Eur Neuropsychopharmacol 2004 14 1 11 28 14659983
  8. [10]Adler LA Mattingly GW Montano CB Newcorn JH Optimizing clinical outcomes across domains of life in adolescents and adults with ADHD J Clin Psychiatry 2011 72 7 1008 1014 21824459
  9. [12]Bussing R Mason DM Bell L Porter P Garvan C Adolescent outcomes of childhood attention-deficit/hyperactivity disorder in a diverse community sample J Am Acad Child Adolesc Psychiatry 2010 49 6 595 605 20494269 PMC2876093
  10. [13]Findling RL Evolution of the treatment of attention-deficit/hyperactivity disorder in children: a review Clin Ther 2008 30 5 942 957 18555941
  11. [14]Connor DF Steingard RJ New formulations of stimulants for attention-deficit hyperactivity disorder: therapeutic potential CNS Drugs 2004 18 14 1011 1030 15584770
  12. [15]Brams M Moon E Pucci M Lopez FA Duration of effect of oral long-acting stimulant medications for ADHD throughout the day Curr Med Res Opin 2010 26 8 1809 1825 20491612
  13. [16]Brams M Mao AR Doyle RL Onset of efficacy of long-acting psychostimulants in pediatric attention-deficit/hyperactivity disorder Postgrad Med 2008 120 3 69 88 18824827
  14. [17]Banaschewski T Coghill D Santosh P Long-acting medications for the hyperkinetic disorders. A systematic review and European treatment guideline Eur Child Adolesc Psychiatry 2006 15 8 476 495 16680409
  15. [19]Ermer J Homolka R Martin P Buckwalter M Purkayastha J Roesch B Lisdexamfetamine dimesylate: linear dose-proportionality, low intersubject and intrasubject variability, and safety in an open-label single-dose pharmacokinetic study in healthy adult volunteers J Clin Pharmacol 2010 50 9 1001 1010 20173084
  16. [20]Najib J The efficacy and safety profile of lisdexamfetamine dimesylate, a prodrug of d-amphetamine, for the treatment of attention-deficit/hyperactivity disorder in children and adults Clin Ther 2009 31 1 142 176 19243715
  17. [21]Boellner SW Stark JG Krishnan S Zhang Y Pharmacokinetics of lisdexamfetamine dimesylate and its active metabolite, d-amphetamine, with increasing oral doses of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: a single-dose, randomized, open-label, crossover study Clin Ther 2010 32 2 252 264 20206783
  18. [22]Biederman J Boellner SW Childress A Lopez FA Krishnan S Zhang Y Lisdexamfetamine dimesylate and mixed amphetamine salts extended-release in children with ADHD: a double-blind, placebo-controlled, crossover analog classroom study Biol Psychiatry 2007 62 9 970 976 17631866
  19. [24]Krishnan S Moncrief S An evaluation of the cytochrome p450 inhibition potential of lisdexamfetamine in human liver microsomes Drug Metab Dispos 2007 35 1 180 184 17035599
  20. [25]Ermer JC Adeyi BA Pucci ML Pharmacokinetic variability of long-acting stimulants in the treatment of children and adults with attention-deficit hyperactivity disorder CNS Drugs 2010 24 12 1009 1025 21090837
  21. [28]Lopez FA Scheckner B Childress AC Physician perception of clinical improvement in children with attention-deficit/hyperactivity disorder: a post hoc comparison of lisdexamfetamine dimesylate and mixed amphetamine salts extended release in a crossover analog classroom study Neuropsychiatr Dis Treat 2011 7 267 273 21654872 PMC3101887
  22. [29]Biederman J Krishnan S Zhang Y McGough JJ Findling RL Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: a phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study Clin Ther 2007 29 3 450 463 17577466
  23. [30]Lopez FA Ginsberg LD Arnold V Effect of lisdexamfetamine dimesylate on parent-rated measures in children aged 6 to 12 years with attention-deficit/hyperactivity disorder: a secondary analysis Postgrad Med 2008 120 3 89 102 18824828
  24. [33]Faraone SV Understanding the effect size of lisdexamfetamine dimesylate for treating ADHD in children and adults J Atten Disord 2012 16 2 128 137 20837983
  25. [36]Findling RL Ginsberg LD Jain R Gao J Effectiveness, safety, and tolerability of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: an open-label, dose-optimization study J Child Adolesc Psychopharmacol 2009 19 6 649 662 20035583
  26. [37]Turgay A Ginsberg L Sarkis E Executive function deficits in children with attention-deficit/hyperactivity disorder and improvement with lisdexamfetamine dimesylate in an open-label study J Child Adolesc Psychopharmacol 2010 20 6 503 511 21186969 PMC3005278
  27. [38]Wigal SB Maltas S Crinella F Reading performance as a function of treatment with lisdexamfetamine dimesylate in elementary school children diagnosed with ADHD J Atten Disord 2012 16 1 23 33 20978273
  28. [39]Findling RL Childress AC Cutler AJ Efficacy and safety of lisdexamfetamine dimesylate in adolescents with attention-deficit/hyperactivity disorder J Am Acad Child Adolesc Psychiatry 2011 50 4 395 405 21421179
  29. [40]Childress AC Long-term safety and effectiveness of lisdexamfetamine dimesylate in adolescents with attention-deficit/hyperactivity disorder Proceedings of the 164th Annual Meeting of the American Psychiatric Association May 14–18, 2011 Honolulu, HI
  30. [42]Coghill DR Tobias B Lecendreux ML Efficacy and safety of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder: a Phase 3, randomized, double-blind, multicenter, parallel-group, placebo-and-active-controlled, dose-optimization study in Europe Proceedings of the American Academy of Child and Adolescent Psychiatry and Canadian Academy of Child and Adolescent Psychiatry Joint Annual Meeting October 18–23, 2011 Toronto, Canada
  31. [43]Katic A Ginsberg L Jain R Clinically relevant changes in emotional expression in children with ADHD treated with lisdexamfetamine dimesylate J Atten Disord 12 20 2011 [Epub ahead of print] 21173426
  32. [44]Faraone SV Spencer TJ Kollins SH Glatt SJ Effects of lisdexamfetamine dimesylate treatment for ADHD on growth J Am Acad Child Adolesc Psychiatry 2010 49 1 24 32 20215923
  33. [45]MTA Cooperative Group A 14-month randomized clinical trial of treatment strategies for attention deficit/hyperactivity disorder Arch Gen Psychiatry 1999 56 12 1073 1086 10591283
  34. [46]Wigal SB Jun A Wong AA Stehli A Steinberg-Epstein R Lerner MA Does prior exposure to stimulants in children with ADHD impact cardiovascular parameters from lisdexamfetamine dimesylate? Postgrad Med 2010 122 5 27 34 20861585
  35. [47]Cooper WO Habel LA Sox CM ADHD drugs and serious cardiovascular events in children and young adults N Engl J Med 2011 365 20 1896 1904 22043968 PMC4943074
  36. [48]Vetter VL Elia J Erickson C Cardiovascular monitoring of children and adolescents with heart disease receiving medications for attention deficit/hyperactivity disorder: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing Circulation 2008 117 18 2407 2423 18427125
  37. [50]Giblin JM Strobel AL Effect of lisdexamfetamine dimesylate on sleep in children with ADHD J Atten Disord 2011 15 6 491 498 20574056
  38. [52]Brahm NC Hamilton DR Alopecia following initiation of lisdexamfetamine in a pediatric patient Prim Care Companion J Clin Psychiatry 2009 11 6 365 20098534 PMC2805578
  39. [53]Hood B Nowicki MJ Eosinophilic hepatitis in an adolescent during lisdexamfetamine dimesylate treatment for ADHD Pediatrics 2010 125 6 e1510 e1513 20457690
  40. [54]Goodman DW Scheckner B Dirks B Safety profile of lisdexamfetamine dimesylate in clinical trials in children, adolescents, and adults with attention-deficit/hyperactivity disorder Proceedings of the 163rd Annual Meeting of the American Psychiatric Association May 22–26, 2011 New Orleans, LA
  41. [55]Wigal SB Chae S Patel A Steinberg-Epstein R Advances in the treatment of attention-deficit/hyperactivity disorder: a guide for pediatric neurologists Semin Pediatr Neurol 2010 17 4 230 236 21183129
  42. [56]Arnold LE Methylphenidate vs amphetamine: comparative review J Atten Disord 2000 3 4 200 211
  43. [58]Jasinski DR Krishnan S Human pharmacology of intravenous lisdexamfetamine dimesylate: abuse liability in adult stimulant abusers J Psychopharmacol 2009 23 4 410 418 18635707
  44. [60]Patrick DL Edwards TC Topolski TD Adolescent quality of life, part II: initial validation of a new instrument J Adolesc 2002 25 3 287 300 12128039
  45. [61]Antonucci D Kunins C Manos M Lopez FA Kerney DL Assessing effects of treatment with lisdexamfetamine dimesylate for pediatric ADHD using a parental survey CNS Spectr 2010 15 4 248 256 20414174

Cited by

Sorted by citations

Authors
Najib, J.
Affiliations
St. Luke's-Roosevelt Hospital Center (US)
Corresponding author
Najib, Jadwiga
Venue
Adolescent Health, Medicine and Therapeutics
Publisher
Informa UK Limited
Published
2012-05
Volume
3
Pages
51
ISSN
1179-318X (ISSN-L)
DOI
10.2147/ahmt.s19815
PMC
PMC3915893
OpenAlex
W2084872911
Cited by
8
References
10
Citations by year
2024: 1 · 2020: 1 · 2018: 1 · 2017: 1 · 2016: 3 · 2014: 1
FWCI
0.04
Type
journal article
Language
en
Open access
Licence
Locations
  • Adolescent Health Medicine and Therapeutics (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
  • Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
  • Health Sciences › Medicine › Pharmacology › Pharmacology and Obesity Treatment
Keywords
lisdexamfetamine dimesylate, attention deficit hyperactivity disorder, children, adolescents, pharmacokinetics, efficacy, drug safety, abuse liability, d-amphetamine, stimulant medication

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review